During the past decade, JHU AVEG conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "JHU AVEG" #1 collaborator was "Protein Sciences Corporation" with 2 trials as a collaborator, "Biocine" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Immuno-US" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "JHU AVEG" are "HIV Infections" (9 trials). Many other conditions were trialed in "JHU AVEG" in a lesser frequency.

Most popular intervention types in "JHU AVEG" are "Biological" (9 trials). Other intervention types were less common.

The name of intervention was led by "gp160 Vaccine (MicroGeneSys)" (3 trials), "rgp120/HIV-1 SF-2" (3 trials), "rgp120/HIV-1MN" (3 trials), "Aluminum hydroxide" (2 trials) and "QS-21" (2 trials). Other intervention names were less common.

The vast majority of trials in "JHU AVEG" are 9 trials for "All" genders.

Currently, there are NaN active trials in "JHU AVEG". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in JHU AVEG, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in JHU AVEG, 8 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".